PARP inhibition in Prostate Cancer: Optimizing Care for Veterans

Get up to date on optimal Veterans Affairs care of patients receiving combination and single-agent PARP inhibitor regimens for prostate cancer with downloadable slides, an on-demand webcast, and expert commentary.

Share

Program Content

Activities

PARPi in Prostate Cancer Webcast
PARP Inhibition in Prostate Cancer: Optimizing Care for Veterans
Video
Congratulations: You achieved a completion on 04/09/2022

Released: April 05, 2024

Expires: April 04, 2025

Activities

PARPi for Prostate Cancer in Veterans
PARP Inhibition in Prostate Cancer: Optimizing Care for Veterans
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 31, 2024

Activities

PARPi for Prostate Cancer FAQ
PARP Inhibitors for Prostate Cancer: Expert Answers to Your Questions
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 09, 2024

Expires: April 08, 2025

Faculty

cover img faculity

Himisha Beltran, MD

Associate Professor of Medicine
Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts 

cover img faculity

Daniel P. Petrylak, MD

Professor of Medicine (Medical Oncology) and of Urology
Director, Prostate and GU Medical Oncology
Yale Cancer Center
New Haven, Connecticut

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.

AstraZeneca

Merck & Co., Inc., Rahway, NJ, USA